Innovative Low-CG Chassis: The Revo chassis is a highly engineered approach that allows incredible strength and lightweight performance not possible with traditional designs. The innovative E-Revo suspension design is unmatched for travel and performance for all types of driving and terrain. The inboard shocks are mounted horizontally to lower the CG and are naturally protected from impacts and debris. Additional benefits include built-in progressive spring rate courtesy of the rocker geometry and the ability to independently change adjustments such as ride height without affecting the damping and spring rate.
Heavy-duty telescoping center driveshafts.Patented waterproof receiver box with easy-access plug.5-channel micro receiver ( tra6533 ) with fail-safe security.High 13ms frame rate and near-zero latency for responsive control.Adjustable steering and throttle end points.Adjustable steering and throttle sensitivity (exponential).Adjustable steering and throttle percentage (dual rates).Automatically stores and loads settings for up to 30 Traxxas Link-enabled models.Adjusts from off to 100% assistance from the transmitter.Never dulls throttle or slows the truck.Improves straight line acceleration and braking on low-traction surfaces.Up to 70+ mph with Two 3s LiPo Batteries.Patented Traxxas High-Current Connectors.VXL-6s™ Waterproof Electronic Speed Control.Necrotizing pneumonia caused by refractory Mycoplasma pneumonia pneumonia in children. Infection by Mycoplasma pneumoniae and its importance as an etiological agent in childhood community-acquired pneumonias. Effects of methylprednisolone pulse therapy on refractory mycoplasma pneumoniae pneumonia in children.
Incidence of community-acquired pneumonia in children caused by Mycoplasma pneumoniae: serological results of a prospective, population-based study in primary health care. Community-acquired pneumonia requiring hospitalization among U.S. The prognostic assessment scale for RMPP has high diagnostic accuracy and is suitable for use in standard clinical practice. 944 children were included in the prospective cohort, including 92 with RMPP, the sensitivity of the prognostic assessment scale was 78.3% (72/92) and the specificity was 86.2% (734/852). The sensitivity of the prognostic assessment scale was 74.0% (54/73), and the specificity was 88.3% (481/545) in the retrospective study. Six prognostic indicators were identified and included in the prognostic assessment scale. 618 children were included in the retrospective study, of which 73 with RMPP. Second we conducted a prospective study to validate the predictive scale for RMPP in children in 2018. Children were divided into two groups, according to whether their pneumonia were refractory and the results were used to develop an early predictive scale. pneumoniae pneumonia admitted to Children's Hospital of Nanjing Medical University, China in 2016. First we conducted a retrospective cohort study of children with M. The aim of this study is to identify indicators and develop an early predictive scale for RMPP in hospitalized children. Now there is no clinical scale for early prediction of refractory Mycoplasma pneumoniae pneumonia (RMPP).
0 kommentar(er)
